Skip to main content

Table 3 Relationships between clinicopathological characteristics and pathological response evaluated by JGCA-TRG system

From: Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China

Characteristics

Total cases (n = 192), no. (%)

JGCA -TRG

P value

3 (n = 11), no. (%)

2 (n = 63), no. (%)

1b (n = 45), no. (%)

1a (n = 33), no. (%)

0 (n = 40), no. (%)

Gender

      

0.097

 Male

139 (72.4)

10 (7.2)

48 (34.5)

30 (21.6)

19 (13.7)

32 (23)

 

 Female

53 (27.6)

1 (1.9)

15 (28.3)

15 (28.3)

14 (26.4)

8 (15.1)

 

Age

      

0.711

 < 55y

89 (46.4)

6 (6.7)

26 (29.2)

24 (27)

16 (18)

17 (19.1)

 

 ≥ 55y

103 (53.6)

5 (4.9)

37 (35.9)

21 (20.4)

17 (16.5)

23 (22.3)

 

Location

      

0.287

 Esophagogastric junction

44 (22.9)

1 (2.3)

12 (27.3)

10 (22.7)

10 (22.7)

11 (25)

 

 Proximal gastric

71 (37)

7 (9.9)

23 (32.4)

15 (21.1)

8 (11.3)

18 (25.4)

 

 Distal gastric

77 (40.1)

3 (3.9)

28 (36.4)

20 (26)

15 (19.5)

11 (14.3)

 

Maximal diameter of tumor bed

      

<0.001

 < 4.5 cm

108 (56.2)

9 (8.3)

40 (37)

27 (25)

17 (15.7)

15 (13.9)

 

 4.5–8 cm

64 (33.3)

1 (1.6)

21 (32.8)

14 (21.9)

12 (18.8)

16 (25)

 

 > 8 cm

20 (10.4)

1 (5)

2 (10)

4 (20)

4 (20)

9 (45)

 

Histological differentiation

      

0.060

 Well-moderate

45 (23.4)

4 (8.9)

21 (46.7)

10 (22.2)

6 (13.3)

4 (8.9)

 

 Poor

147 (76.6)

7 (4.8)

42 (28.6)

35 (23.8)

27 (18.4)

36 (24.5)

 

Laurén classification

       

 Intestinal

77 (40.1)

4 (5.2)

29 (37.7)

18 (23.4)

11 (14.3)

15 (19.5)

 

 Diffuse

73 (38)

7 (9.6)

20 (27.4)

16 (21.9)

16 (21.9)

14 (19.2)

 

 Mixed

42 (21.9)

0 (0)

14 (33.3)

11 (26.2)

6 (14.3)

11 (26.2)

 

LVI

      

<0.001

 Negative

94 (49)

11 (11.7)

46 (48.9)

19 (20.2)

8 (8.5)

10 (10.6)

 

 Positive

98 (51)

0 (0)

17 (17.3)

26 (26.5)

25 (25.5)

30 (30.6)

 

PNI

      

<0.001

 Negative

76 (39.6)

11 (14.5)

35 (46.1)

14 (18.4)

9 (11.8)

7 (9.2)

 

 Positive

116 (60.4)

0 (0)

28 (24.1)

31 (26.7)

24 (20.7)

33 (28.4)

 

AJCC ypT category

      

<0.001

 0

11 (5.7)

11 (100)

0 (0)

0 (0)

0 (0)

0 (0)

 

 1

20 (10.4)

0 (0)

17 (85)

1 (5)

2 (10)

0 (0)

 

 2

23 (12)

0 (0)

11 (47.8)

6 (26.1)

6 (26.1)

0 (0)

 

 3

57 (29.7)

0 (0)

24 (42.1)

16 (28.1)

8 (14)

9 (15.8)

 

 4

81 (42.2)

0 (0)

11 (13.6)

22 (27.2)

17 (21)

31 (38.3)

 

AJCC ypN category

      

<0.001

 0

55 (28.6)

9 (16.4)

30 (54.5)

5 (9.1)

5 (9.1)

6 (10.9)

 

 1

36 (18.8)

0 (0)

13 (26)

11 (30.6)

5 (13.9)

7 (19.4)

 

 2

50 (26)

0 (0)

13 (26)

21 (42)

11 (22)

5 (10)

 

 3

51 (26.6)

2 (3.9)

7 (13.7)

8 (15.7)

12 (23.5)

22 (43.1)

 

AJCC stage

      

<0.001

 0

9 (4.7)

9 (100)

0 (0)

0 (0)

0 (0)

0 (0)

 

 1

24 (12.5)

0 (0)

21 (87.5)

1 (4.2)

1 (4.2)

1 (4.2)

 

 2

53 (27.6)

2 (3.8)

20 (37.7)

12 (22.6)

9 (17)

10 (18.9)

 

 3

106 (55.2)

0 (0)

22 (20.8)

32 (30.2)

23 (21.7)

29 (27.4)

 

R0 resection

      

0.046

 Yes

159 (82.8)

11 (6.9)

55 (34.6)

40 (25.2)

24 (15.1)

29 (18.2)

 

 No

33 (17.2)

0 (0)

8 (24.2)

5 (15.2)

9 (27.3)

11 (33.3)

 

Adjuvant chemotherapy

      

0.676

 Not received

59 (30.7)

3 (5.1)

16 (27.1)

13 (22)

12 (20.3)

15 (25.4)

 

 Received

133 (69.3)

8 (6)

47 (35.3)

32 (24.1)

21 (15.8)

25 (18.8)

 
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us